Showing 831-840 of 1236 results for "".
Global Aesthetics: Laser Advances
https://modernaesthetics.com/topics/energy-based-devices/global-aesthetics-laser-advances/35224/Focal point technology lasers have the potential to fill a void in the aesthetic market for darker skin types.Coming & Going: July/August 2022
https://modernaesthetics.com/topics/injectables/coming-going-july-august-2022/35196/Coming & Going: July/August 2021
https://modernaesthetics.com/topics/energy-based-devices/coming-going-julyaugust-2021/35068/Fix These Website Flaws Now
https://modernaesthetics.com/ma-issues-index/2018-may-june/fix-these-website-flaws-now/34113/Simple coding errors may be sabotaging your rankings.VASER: Targeting Fat; Redefining Success
https://modernaesthetics.com/ma-supplements/2018-mar-apr-supplement/vaser-targeting-fat-redefining-success/34168/A safe and versatile system, VASER is reshaping the approach to fat reduction and body contouring.Safety Dance: HTTPS Update
https://modernaesthetics.com/ma-issues-index/2017-nov-dec/safety-dance-https-update/34216/Is HTTPS really worth jumping through hoops for an aesthetic practice?Imaging Device Offers 3D Demonstration of Procedure Outcomes
https://modernaesthetics.com/ma-issues-index/2014-mar-apr/imaging-device-offers-3d-demonstration-of-procedure-outcomes/34648/New Products
https://modernaesthetics.com/ma-issues-index/2023-may-june/new-products-9/35273/Mental Health: BDD, OCD, Psychosis
https://beta.modernaesthetics.com/conferences/tell-all-tribune/mental-health-bdd-ocd-psychosis/33790/Richard Fried, MD, PhD, FAAD, discusses how aesthetic physicians must navigate challenging patient interactions with individuals who have body dysmorphic disorder (BDD), OCD, narcissistic personality disorder, and psychosis at the 2024 Tell-All Tribune: An Aesthetic Think Tank. Patients with BDD may- Breaking Business News: Apax Partners to Acquire Syneronhttps://modernaesthetics.com/news/breaking-business-news-apax-partner-to-acquire-syneron/2472253/An affiliate of funds advised by Apax Partners will acquire all of the outstanding shares of Syneron Candela for $11.00 per share in cash in a transaction valued at approximately $397 million. The per share acquisition price represe